39341977|t|The association between antiglaucomatous agents and Alzheimer's disease.
39341977|a|OBJECTIVES: To estimate the risk of Alzheimer's disease (AD) associated with long-term use of topical glaucoma medications among middle-aged and older glaucoma patients, and compare the AD risk among various glaucoma subtypes. METHODS: This nationwide population-based cohort study utilized insurance claims data from Taiwan's National Health Insurance Research Database between 2008 and 2019. Participants were adults aged 45 years or older either with a diagnosis of glaucoma or without. Those with glaucoma must have received single antiglaucomatous medication (including alpha2-adrenergic agonists, cholinergic agonists, beta-blockers, prostaglandin analogs, and pilocarpine) for over 90 days. Those with pre-existing AD diagnoses prior to the index date were excluded. RESULTS: A total of 202,000 participants were included in the study, with 101,000 in each group (glaucoma and control groups). Glaucoma patients on topical alpha-2 adrenergic agonist monotherapy exhibited a significantly higher AD risk (aHR 1.15, 95% CI = 1.01-1.31) compared to those on beta-blockers. Glaucoma was further categorized into primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG), primary angle-closure glaucoma (PACG), and unspecified glaucoma. Irrespective of the type of glaucoma, individuals with glaucoma had a significantly higher risk of AD compared to those without glaucoma (POAG: aHR 1.23, 95% CI = 1.08-1.40; NTG: aHR 1.49, 95% CI = 1.19-1.85; PACG: aHR 1.35, 95% CI = 1.19-1.52; unspecified glaucoma: aHR 1.36, 95% CI = 1.23-1.50). CONCLUSIONS: Topical alpha-2 adrenergic agonists might pose increased AD risk in individuals with glaucoma compared to beta-blockers. Accordingly, their utilization should be undertaken judiciously, especially in middle-aged and older populations. Our findings also indicate glaucoma may increase the risk of AD regardless of glaucoma subtype.
39341977	52	71	Alzheimer's disease	Disease	MESH:D000544
39341977	109	128	Alzheimer's disease	Disease	MESH:D000544
39341977	130	132	AD	Disease	MESH:D000544
39341977	175	195	glaucoma medications	Disease	MESH:D005901
39341977	224	232	glaucoma	Disease	MESH:D005901
39341977	233	241	patients	Species	9606
39341977	259	261	AD	Disease	MESH:D000544
39341977	281	289	glaucoma	Disease	MESH:D005901
39341977	542	550	glaucoma	Disease	MESH:D005901
39341977	574	582	glaucoma	Disease	MESH:D005901
39341977	713	734	prostaglandin analogs	Chemical	MESH:D011465
39341977	740	751	pilocarpine	Chemical	MESH:D010862
39341977	795	797	AD	Disease	MESH:D000544
39341977	944	952	glaucoma	Disease	MESH:D005901
39341977	974	982	Glaucoma	Disease	MESH:D005901
39341977	983	991	patients	Species	9606
39341977	1075	1077	AD	Disease	MESH:D000544
39341977	1150	1158	Glaucoma	Disease	MESH:D005901
39341977	1188	1215	primary open-angle glaucoma	Disease	MESH:D005902
39341977	1217	1221	POAG	Disease	MESH:D005902
39341977	1224	1247	normal-tension glaucoma	Disease	MESH:D057066
39341977	1249	1252	NTG	Disease	MESH:D057066
39341977	1255	1285	primary angle-closure glaucoma	Disease	MESH:D015812
39341977	1287	1291	PACG	Disease	MESH:D015812
39341977	1310	1318	glaucoma	Disease	MESH:D005901
39341977	1348	1356	glaucoma	Disease	MESH:D005901
39341977	1375	1383	glaucoma	Disease	MESH:D005901
39341977	1419	1421	AD	Disease	MESH:D000544
39341977	1448	1456	glaucoma	Disease	MESH:D005901
39341977	1458	1462	POAG	Disease	MESH:D005902
39341977	1494	1497	NTG	Disease	MESH:D057066
39341977	1529	1533	PACG	Disease	MESH:D015812
39341977	1577	1585	glaucoma	Disease	MESH:D005901
39341977	1688	1690	AD	Disease	MESH:D000544
39341977	1716	1724	glaucoma	Disease	MESH:D005901
39341977	1893	1901	glaucoma	Disease	MESH:D005901
39341977	1927	1929	AD	Disease	MESH:D000544
39341977	1944	1952	glaucoma	Disease	MESH:D005901
39341977	Negative_Correlation	MESH:D011465	MESH:D005901
39341977	Negative_Correlation	MESH:D010862	MESH:D005901

